Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of CM-101 in in patients with liver fibrosis

X
Trial Profile

Phase 2 study of CM-101 in in patients with liver fibrosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 101 (Primary)
  • Indications Hepatic fibrosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Chemomab Therapeutics
  • Most Recent Events

    • 13 Nov 2023 According to a Chemomab Therapeutics media release, findings from proteomic analyses of serum samples at baseline and after 16 weeks of treatment with CM-101 from this trial were presented at the AASLD's The Liver Meeting 2023.
    • 13 Nov 2023 Results presented in the Chemomab Therapeutics Media Release.
    • 21 Jun 2023 According to a Chemomab Therapeutics media release, company reported reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101, its first-in-class CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH). The results were included in a late-breaking poster presentation at the 2023 EASL Congress in Vienna, Austria.1
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top